Utilizing signature-score to identify oncogenic pathways of cholangiocarcinoma.

Extracting maximal information from gene signature sets (GSSs) via microarray-based transcriptional profiling involves assigning function to up and down regulated genes. Here we present a novel sample scoring method called Signature-score (S-score) which can be used to quantify the expression pattern of tumor samples from previously identified gene signature sets. A simulation result demonstrated an improved accuracy and robustness by S-score method comparing with other scoring methods. By applying the S-score method to cholangiocarcinoma (CAC), an aggressive hepatic cancer that arises from bile ducts cells, we identified enriched oncogenic pathways in two large CAC data sets. Thirteen pathways were enriched in CAC compared with normal liver and bile duct. Moreover, using S-score, we were able to dissect correlations between CAC-associated oncogenic pathways and Gene Ontology function. Two major oncogenic clusters and associated functions were identified. Cluster 1, which included beta-catenin and Ras, showed a positive correlation with the cell cycle, while cluster 2, which included TGF-beta, cytokeratin 19 and EpCAM was inversely correlated with immune function. We also used S-score to identify pathways that are differentially expressed in CAC and hepatocellular carcinoma (HCC), the more common subtype of liver cancer. Our results demonstrate the utility and effectiveness of S-score in assigning functional roles to tumor-associated gene signature sets and in identifying potential therapeutic targets for specific liver cancer subtypes.

[1]  Dirk Troost,et al.  Integrated Genomics Identifies Five Medulloblastoma Subtypes with Distinct Genetic Profiles, Pathway Signatures and Clinicopathological Features , 2008, PloS one.

[2]  F. Eckel,et al.  Chemotherapy in advanced biliary tract carcinoma: a pooled analysis of clinical trials , 2007, British Journal of Cancer.

[3]  Benjamin R Arenkiel,et al.  Evidence for an unanticipated relationship between undifferentiated pleomorphic sarcoma and embryonal rhabdomyosarcoma. , 2011, Cancer cell.

[4]  S. Thorgeirsson,et al.  Progenitor‐derived hepatocellular carcinoma model in the rat , 2010, Hepatology.

[5]  S. Thorgeirsson,et al.  A novel prognostic subtype of human hepatocellular carcinoma derived from hepatic progenitor cells , 2006, Nature Medicine.

[6]  Justin Guinney,et al.  Predictive Genes in Adjacent Normal Tissue Are Preferentially Altered by sCNV during Tumorigenesis in Liver Cancer and May Rate Limiting , 2011, PloS one.

[7]  P. Hall,et al.  An expression signature for p53 status in human breast cancer predicts mutation status, transcriptional effects, and patient survival. , 2005, Proceedings of the National Academy of Sciences of the United States of America.

[8]  B. Yoong,et al.  Survival analysis of cholangiocarcinoma: a 10-year experience in Malaysia. , 2012, World journal of gastroenterology.

[9]  A. Olshen,et al.  Global gene expression profiling of PAX‐FKHR fusion‐positive alveolar and PAX‐FKHR fusion‐negative embryonal rhabdomyosarcomas , 2007, The Journal of pathology.

[10]  P. Callard,et al.  Distinction between hepatocellular carcinoma, cholangiocarcinoma, and metastatic carcinoma based on immunohistochemical staining for carcinoembryonic antigen and for cytokeratin 19 on paraffin sections , 1988, The Journal of pathology.

[11]  Michael L. Gatza,et al.  A pathway-based classification of human breast cancer , 2010, Proceedings of the National Academy of Sciences.

[12]  S. Serra,et al.  The Use of Cytokeratin 19 (CK19) Immunohistochemistry in Lesions of the Pancreas, Gastrointestinal Tract, and Liver , 2010, Applied immunohistochemistry & molecular morphology : AIMM.

[13]  G. Fava Molecular mechanisms of cholangiocarcinoma. , 2010, World journal of gastrointestinal pathophysiology.

[14]  Seiichi Mori,et al.  An E2F1-dependent gene expression program that determines the balance between proliferation and cell death. , 2008, Cancer cell.

[15]  H. El‐Serag,et al.  The epidemiology of cholangiocarcinoma. , 2004, Seminars in liver disease.

[16]  A. Chinnaiyan,et al.  Activation of mitogen-activated protein kinase in estrogen receptor alpha-positive breast cancer cells in vitro induces an in vivo molecular phenotype of estrogen receptor alpha-negative human breast tumors. , 2006, Cancer research.

[17]  Y. Konishi,et al.  Ki-ras mutations and p53 protein expressions in intrahepatic cholangiocarcinomas: relation to gross tumor morphology. , 1995, Gastroenterology.

[18]  Ash A. Alizadeh,et al.  Gene Expression Signature of Fibroblast Serum Response Predicts Human Cancer Progression: Similarities between Tumors and Wounds , 2004, PLoS biology.

[19]  F. Sommerer,et al.  Mutations of the BRAF gene in cholangiocarcinoma but not in hepatocellular carcinoma , 2003, Gut.

[20]  Ben S. Wittner,et al.  Systematic RNA interference reveals that oncogenic KRAS-driven cancers require TBK1 , 2009, Nature.

[21]  S. Thorgeirsson,et al.  Transforming growth factor‐β gene expression signature in mouse hepatocytes predicts clinical outcome in human cancer , 2008, Hepatology.

[22]  R. Young,et al.  A common set of gene regulatory networks links metabolism and growth inhibition. , 2004, Molecular cell.

[23]  K. Arihiro,et al.  Immunohistochemical and mutational analyses of Wnt signaling components and target genes in intrahepatic cholangiocarcinomas. , 2005, International journal of oncology.

[24]  W. Palmer,et al.  Are common factors involved in the pathogenesis of primary liver cancers? A meta-analysis of risk factors for intrahepatic cholangiocarcinoma. , 2012, Journal of hepatology.

[25]  Jin Woo Kim,et al.  EpCAM and alpha-fetoprotein expression defines novel prognostic subtypes of hepatocellular carcinoma. , 2008, Cancer research.

[26]  Dror Berel,et al.  Expression Signatures of Metastatic Capacity in a Genetic Mouse Model of Lung Adenocarcinoma , 2009, PloS one.

[27]  A. Chinnaiyan,et al.  Activation of mitogen-activated protein kinase in estrogen receptor alpha-positive breast cancer cells in vitro induces an in vivo molecular phenotype of estrogen receptor alpha-negative human breast tumors. , 2006, Cancer research.

[28]  P. Bosma,et al.  Selection of tumour specific promoters for adenoviral gene therapy of cholangiocarcinoma. , 2006, Journal of hepatology.

[29]  Itzhak Avital,et al.  Genomic and genetic characterization of cholangiocarcinoma identifies therapeutic targets for tyrosine kinase inhibitors. , 2012, Gastroenterology.

[30]  Shuta Tomida,et al.  Relationship of deregulated signaling converging onto mTOR with prognosis and classification of lung adenocarcinoma shown by two independent in silico analyses. , 2009, Cancer research.

[31]  Harada,et al.  Protein expression and genetic alterations of p53 and ras in intrahepatic cholangiocarcinoma , 1999, Histopathology.

[32]  Hideaki Mizuno,et al.  A signature-based method for indexing cell cycle phase distribution from microarray profiles , 2009, BMC Genomics.

[33]  Jeffrey M. Rosen,et al.  Residual breast cancers after conventional therapy display mesenchymal as well as tumor-initiating features , 2009, Proceedings of the National Academy of Sciences.

[34]  R. Hruban,et al.  Differing rates of loss of DPC4 expression and of p53 overexpression among carcinomas of the proximal and distal bile ducts , 2001, Cancer.

[35]  M. Grever,et al.  Multi-institutional phase II study of selumetinib in patients with metastatic biliary cancers. , 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[36]  Pablo Tamayo,et al.  Gene set enrichment analysis: A knowledge-based approach for interpreting genome-wide expression profiles , 2005, Proceedings of the National Academy of Sciences of the United States of America.

[37]  Jung-Hwan Yoon,et al.  Identification of a cholangiocarcinoma-like gene expression trait in hepatocellular carcinoma. , 2010, Cancer research.